Memory and Cancer: A Review of the Literature

Archives of Psychiatric Nursing

Volumn 28, Issue 3, 2014, Pages 180-186

  McDougall, Graham J ^a   Oliver, JoAnn S ^a   Scogin, Forrest ^b  

^a UNIVERSITY OF ALABAMA   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADAPTIVE BEHAVIOR; ADULT; AGED; CHEMICALLY INDUCED; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEOPLASMS; NURSING; PSYCHOLOGY; RECALL; SURVIVOR;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MENTAL RECALL; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NEOPLASMS; SURVIVORS;

EID: 84901282678     PISSN: 08839417     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.apnu.2013.12.005     Document Type: Article

References (103)

1. Ahles T.A. Brain vulnerability to chemotherapy toxicities. Psycho-Oncology 2012, 21:1141-1148.
2. Ahles T.A., Root J.C., Ryan E.L. Cancer- and cancer treatment-associated cognitive change: An update on the state of the science. Journal Clinical Oncology 2012, 30(30):3675-3686.
3. Ahles T.A., Saykin A.J., Furstenberg C.T., Cole B., Mott L.A., Skalla K., et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology 2002, 15(2):485-493.
4. Ahles T.A., Saykin A.J., McDonald B.C., Furstenberg C.T., Cole B.F., Hanscom B.S., et al. Cognitive function in breast cancer patients prior to adjuvant treatment. Breast Cancer Research and Treatment 2008, 110(1):143-152.
5. Anderson-Hanley C., Sherman M.L., Riggs R., Agocha V.B., Compas B.E. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. Journal of the International Neuropsychological Society 2003, 9(7):967-892.
6. Beer T.M., Bland L.B., Bussiere J.R., Neiss M.B., Wersinger E.M., Garzotto M., et al. Testosterone loss and estradiol administration modify memory in men. Journal Urology 2006, 175(1):130-135.
7. Bellizzi K.M., Aziz N.M., Rowland J.H., Weaver K., Arora N.K., Hamilton A.S., et al. Double jeopardy? Age, race, and HRQOL in older adults with cancer. Journal Cancer Epidemiology 2012, 10.1155/2012/478642.
8. Bender C.M., Sereika S.M., Berga S.L., Vogel V.G., Brufsky A.M., Paraska K.K., et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 2006, 15(5):422-430.
9. Bennett H.E., Bishop M., Zadik T.D., Lincon N.B. Cognitive impairment after transurethral resection of the prostate. Disability and Rehabilitation 2004, 26(23):1381-1387.
10. Blanchard C.M., Stein K.D., Baker F., Dent M.F., Denniston M.M., Courneya K.S., et al. Association between current lifestyle behaviors and health-related quality of life in breast, colorectal, and prostate cancer survivors. Psychology & Health 2004, 19(1):1-13.
11. Bower J.E., Ganz P.A., Desmond K.A., Rowland J.H., Meyerowitz B.E., Belin T.R. Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. Journal of Clinical Oncology 2000, 18(4):743-753.
12. Caplette-Gingras A., Savard J. Depression in women with metastatic breast cancer: A review of the literature. Palliative & Support Care 2008, 4:377-387.
13. Castellon S.A., Ganz P.A., Bower J.E., Petersen L., Abraham L., Greendale G.A. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. Journal of Clinical and Experimental Neuropsychology 2004, 26(7):955-969.
14. Cherrier M.M. Androgens and cognitive function. Journal Endocrinological Investigation 2005, 28(3 Suppl):65-75.
15. Cherrier M.M., Aubin S., Higino Cognitive and mood changes in men undergoing intermittent combined androgen blockage for non-metastatic prostate cancer. Psycho-Oncology 2009, 8:237-247.
16. Cherrier M.M., Rose A.L., Higano C. The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer. Journal of Urology 2003, 170(5):1808-1811.
17. Choa H.H., Uchio E., Zhang S., Hu S., Bednarski S.R., Luo X., et al. Effects of androgen deprivation on brain function in prostate cancer patients - A prospective observational cohort analysis. BMC Cancer 2012, 12(371).
18. Cimprich B. Attentional fatigue following breast cancer surgery. Research in Nursing & Health 1992, 15:199-207.
19. Cimprich B. Symptom management: Loss of concentration. Seminars in Oncology Nursing 1995, 11:279-288.
20. Collins B., Mackenzie J., Tasca G.A., Scherling C., Smith A. Cognitive effects of chemotherapy in breast cancer patients: A dose-response study. Psycho-Oncology 2009, 18(2):134-143.
21. Costanzo E.S., Ryff C.D., Singer B.H. Psychosocial adjustment among cancer survivors: Findings from a national survey of health and well-being. Health Psychology 2009, 28(2):147-156.
22. Courneya K.S., Friedenreich C.M. Relationship between exercise pattern across the cancer experience and current quality of life in colorectal cancer survivors. The Journal of Alternative and Complementary Medicine 1997, 3(3):215-226.
23. Cull A., Hay C., Love S.B., Mackie M., Smets E., Stewart M. What do cancer patients mean when they complain of concentration and memory problems?. British Journal of Cancer 1996, 74:1674-1679.
24. Demark-Wahnefried W., Aziz N.M., Rowland J.H., Pinto B.M. Riding the crest of the teachable moment: Promoting long-term health after the diagnosis of cancer. Journal of Clinical Oncology 2005, 23(24):5814-5830.
25. Donovan K.A., Small B.J., Andrykowski M.A., Schmitt F.A., Munster P., Jacobsen P.B. Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 2004, 104(11):2499-2507.
26. Dugbartey A.T., Rosenbaum G., Sanchez P.N., Townes B.D. Neuropsychological assessment of executive functions. Seminars in Neuropsychiatry 1999, 4(1):5-12.
27. Earle C.C., Burstein H.J., Winer E.P., Weeks J.C. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. Journal of Clinical Oncology 2003, 21(8):1447-1451.
28. Eberhardt B., Dilger S., Musial F., Wedding U., Weiss T., Miltner W.H. Short-term monitoring of cognitive functions before and during the first course of treatment. Journal Cancer Research and, Clinical Oncology 2006, 132(4):234-240.
29. Engstrom C.A. Hot flashes in prostate cancer: State of the science. American Journal Men's Health 2008, 2(2):122-132.
30. Falleti M.G., Sanfilippo A., Maruff P., Weih L., Phillips K.A. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain and Cognition 2005, 59(1):60-70.
31. Fann J.R., Thomas-Rich A.M., Katon W.J., Cowley D., Pepping M., McGregor B.A., et al. Major depression after breast cancer: A review of epidemiology and treatment. General Hospital Psychiatry 2008, 30(2):112-126.
32. Ferguson R.J., Ahles T.A., Saykin A.J., McDonald B.C., Furstenberg C.F., Cole B.F., et al. Cognitive-behavioral management of chemotherapy-related cognitive change. Psycho-Oncology 2007, 16(8):772-777.
33. Ferguson R.J., McDonald B.C., Rocque M.A., Furstenberg C.T., Horrigan S., Ahles T.A., et al. Development of CBT for chemotherapy-related cognitive change: Results of a waitlist control trial. Psycho-Oncology 2012, 21(2):176-186.
34. Freedland S.J., Humphreys E.B., Mangold L.A., Eisenberger M., Dorey F.J., Walsh P.C., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005, 294:433-439.
35. Ganz P.A. Cognitive dysfunction following adjuvant treatment of breast cancer: A new dose-limiting toxic effect?. Journal of the National Cancer Institute 1998, 90:182-183.
36. Ganz P.A. Late effects of cancer and its treatment. Seminars in Oncology Nursing 2001, 17:241-248.
37. Garman K.S., Pieper C.F., Seo P., Cohen H.J. Function in elderly cancer survivors depends on comorbidities. Journal of Gerontology: MEDICAL SCIENCES 2003, 58A(12):1119-1124.
38. Gonzalez E.C., Ferrante J.M., Van Durme D.J., Pal N., Roetzheim R.G. Comorbid illness and the early detection of cancer. Southern Medical Journal 2001, 94(9):4338-4348.
39. Goodwin J.S., Smaet J.W., Hunt W.C. Determinants of survival in older cancer patients. Journal of the National Cancer Institute 1998, 88(15):1031-1038.
40. Green H.J., Pakenham K.I., Headley B.C., Yaxley J., Nicol D.L., Mactaggart P.N., et al. Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: A randomized controlled trial. British Journal of Urology 2002, 90(4).
41. Greiner P.A., Snowdon D.A., Schmitt F.A. The loss of independence in activities of daily living: The role of low normal cognitive function in elderly nuns. American Journal Public Health 1996, 86(1):62-66.
42. Heflin L.H., Meyerowitz B.E., Hall P., Lichtenstein P., Johansson B., Pedersen N.L., et al. Cancer as a risk factor for long-term cognitive deficits and dementia. Cancer Institute 2005, 97(11):854-856.
43. Hodgson K.D., Hutchinson A.D., Wilson C.J., Nettelbeck T. A meta-analysis of the effects of chemotherapy on cognition in patients with cancer. Cancer Treatment Review 2013, 39(3):297-304.
44. Hoffman K.E., McCarthy E.P., Recklitis C.J., Ng A.K. Psychological distress in long-term survivors of adult-onset cancer: Results from a national survey. Archives of Internal Medicine 2009, 169(14):1274-1281.
45. Hughes K.K. Decision making by patients with breast cancer: The role of information in treatment selection. Oncology Nursing Forum 1993, 20:623-628.
46. Hurria A., Rosen C., Hudis C., Zuckerman E., Panageas K.S., Lachs M.S., et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer. Journal American Geriatrics Society 2006, 54(6):925-931.
47. Jamadar R.J., Winters M.J., Maki P.M. Cognitive changes associated with ADT: A review of the literature. Asian Journal Andrology 2012, 14(2):232-238.
48. Jansen C.E., Miaskowski C.A., Dodd M.J., Dowling G.A. A meta-analysis of the sensitivity of various neuropsychological tests used to detect chemotherapy-induced cognitive impairment in patients with breast cancer. Oncology Nursing Forum 2007, 34(5):997-1005.
49. Jansen C.E., Miaskowski C., Dodd M., Dowling G., Kramer J. A meta analysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005, 104(10):2222-2233.
50. Jean-Pierre P., Winters P.C., Ahles T.A., Antoni M., Armstrong F.D., Penedo F., et al. Prevalence of self-reported memory problems in adult cancer survivors: A national cross-sectional study. Journal of Oncology Practice 2012, 8(1):30-34.
51. Jim H.S., Phillips K.M., Chait S., Faul L.A., Popa M.A., Lee Y.H., et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. Journal of Clinical Oncology 2012, 30(29):3578-3587.
52. Joly F., Rigal O., Noal S., Giffard B. Cognitive dysfunction and cancer: Which consequences in terms of disease management?. Psycho-Oncology 2011, 20:1251-1258.
53. Kayl A.E., Wefel J.S., Meyers C.A. Chemotherapy and cognition: Effects, potential mechanisms, and management. American Journal of Therapeutics 2006, 13(4):362-369.
54. Keating N.L., Norredam, Landrum M.B., Haskump H.A., Meara E. Physical and mental health status of older long-term cancer survivors. Journal of the American Geriatrics Society 2005, 53(12):2145-2152.
55. Kenny A.M., Fabregas G., Song C., Biskup B., Bellantonio S. Effects of testosterone on behavior, depression, and cognitive function in older men with mild cognitive loss. Bio/Medical 2004, 591:75-80.
56. Knight S.J., Chmiel J.S., Sharp L.K., Kuzel T., Nadler R.B., Fine R., et al. Spouse rating of quality of life in patients with metastatic prostate cancer of lower socioeconomic status: An assessment of feasibility, reliability, and validity. Urology 2001, 57(2):275-280.
57. Koppelmans V., Breteler M.M., Boogerd W., Seynaeve C., Gundy C., Schagen S.B. Neuropsychological performance in survivors of breast cancer more than 20 years after adjuvant chemotherapy. Journal Clinical Oncology 2012, 30(10):1080-1086.
58. Kune S., Kune G.A., Watson L.F. Observations on the reliability and validity of the design and diet history method in the Melbourne Colorectal Cancer Study. Nutrition and Cancer 1987, 9(1):5-20.
59. Legler J., Potosky A.L., Gilliland F.D., Eley J.W., Stanford J.L. Validation study of retrospective recall of disease-targeted function: Results from the prostate cancer outcomes study. Medical Care 2000, 38(8):847-857.
60. Liu K., Wall S., Wissoker D. Disability and Medicare costs of elderly persons. The Milbank Quarterly 1997, 75(4):461-493.
61. Matsuda T., Takayama T., Tashiro M., Nakamura Y., Ohashi Y., Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients-evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer 2005, 12(4):279-287.
62. McDougall G.J. Cognitive interventions among cancer survivors. Annual Review of Nursing Research 1999, 17:219-240.
63. McDougall G.J. Memory improvement program for elderly cancer survivors. Geriatric Nursing 2001, 22(4):185-190.
64. McDougall G.J., Becker H., Vaughan P., Acee T., Delville C. Symptom management of affective and cognitive disturbance with a group of cancer survivors. Archives Psychiatric Nursing 2011, 25(1):24-35.
65. Miles B.J., Giesler B., Kattan M.W. Recall and attitudes in patients with prostate cancer. Urology 1999, 53:169-174.
66. Minisini A., Atalay G., Bottomley A., Puglisi F., Piccart M., Biganzoli L. What is the effect of systemic anticancer treatment on cognitive function?. Lancet Oncology 2004, 5(5):273-282.
67. Mohile S.G., Lacy M., Rodin M., Bylow K., Dale W., Meager M.R., et al. Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancer. Critical Reviews of Oncology and Hematology 2010, 75(2):152-159.
68. Myers J.S., Valmi D., Sousa V.D., Heidi S., Donovan H.S. Predictors of self-reported memory problems in patients with ovarian cancer who have received chemotherapy. Oncology Nursing Forum 2010, 37(5):596-603.
69. National Cancer Institute Life after cancer treatment (Facing Forward Series No. 04-2424) 2004, (Rockville, MD).
70. National Cancer Institute Lifetime risk (percent) of being diagnosed with cancer by site, race, and sex (DevCan software, version 6.0) 2005, April, (Rockville, MD: Author. Retrieved from http://srab.cancer.gov/devcan/).
71. National Institutes of Health. State-of-the-Science Conference Statement on Improving End-of-Life Care. (December 6-8, 2004) 2004, (Bethesda, MD).
72. Office of Cancer Survivorship Estimated U.S. Cancer Prevalence 2010, National Cancer Institute, (http://cancercontrol.cancer.gov/ocs/prevalence/prevalence.html#survivor).
73. Olin J.J. Cognitive function after systemic therapy for breast cancer. Oncology 2001, 15(5):613-618.
74. Perkina A.V., Poroshina T.E., Kovalenko I.G., Berstein L.M. Cognitive function in patients with endometrial and colorectal cancer: Connection with hormonal and metabolic status. Voprosy Onkologii 2004, 50(5):544-549.
75. Perkins E.A., Small B.J., Balducci L., Extermann M., Robb C., Haley W.E. Individual differences in well-being in older breast cancer survivors. Critical Review Oncology and Hematology 2007, 62(1):74-83.
76. Pollack L., Greer G., Rowland J., Miller A., Doneski D., Coughlin S.S., et al. Cancer survivorship: A new challenge in comprehensive cancer control. Cancer Causes and Control 2005, 16(Suppl. 1):51-59.
77. Poppelreuter M., Weis J., Kulz A.K., Tucha O., Lange K.W., Bartsch H.H. Cognitive dysfunction and subjective complaints of cancer patients. A cross-sectional study in a cancer rehabilitation centre. European Journal Cancer 2004, 40(1):43-49.
78. Ramsey S.D., Berry K., Moinpour C., Giedzinska A., Andersen M.R. Quality of life in long term survivors of colorectal cancer. The American Journal of Gastroenterology 2002, 97(5):1228-1234.
79. Sapp A.L., Trentham-Dietz A., Newcomb P.A., Hampton J.M., Moinpour C.M., Remington P.L. Social networks and quality of life among female long-term colorectal cancer survivors. Cancer 2003, 98(8):1749-1758.
80. Saykin A.J., Ahles T.A., McDonald B.C. Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, pathophysiological, and neuroimaging perspectives. Seminars in clinical Neuropsychiatry 2003, 8(4):201-216.
81. Schagen S.B., van Dam F.S., Muller M.J., Boogerd W., Lindeboom J., Bruning P.F. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999, 85:640-650.
82. Schaie K.W. The hazards of cognitive aging. The Gerontologist 1989, 29(4):484-493.
83. Schultz A.A., Winstead-Fry P. Predictors of quality of life in rural patients with cancer. Cancer Nursing 2001, 24(1):12-19.
84. Segar M.L., Katch V.L., Roth R.S., Garcia A.W., Portner T.I., Glickman S.G., et al. The effect of aerobic exercise on self-esteem and depressive and anxiety symptoms among breast cancer survivors. Oncology Nursing Forum 1998, 25(1):107-113.
85. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Archives of Internal Medicine 2006, 166:465-471.
86. Stewart A., Collins B., Mackenzie J., Tomiak E., Verma S., Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: A prospective study. Psycho-Oncology 2008, 17(2):122-130.
87. Summers L.E. Effects of chemotherapy on patients' cognitive function. Cancer Nursing Practice 2012, 11(8):27-31.
88. Tan W.W., Heckman M.G., Vishnu P., Crook J.E., et al. Effects of leuprolide on serum amyloid-β peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology 2013, 81:150-154.
89. Tannock I.F., Ahles T.A., Ganz P.A., van Dam F.S. Cognitive impairment associated with chemotherapy for cancer: Report of a workshop. Journal of Clinical Oncology 2004, 22(11):2233-2239.
90. Taxel P., Stevens M.C., Trahiotis M., Zimmerman J., Kaplan R.F. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. Journal American Geriatrics Society 2004, 52(2):316-318.
91. Todd B.L., Feuerstein E.L., Feuerstein M. When breast cancer survivors report cognitive problems at work. International Journal Psychiatry in Medicine 2011, 42(3):279-294.
92. van Dam F.S., Schagen S.B., Muller M.J., Boogerd W., Wall E., Fortuyn M.E.D., et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute 1998, 90:210-218.
93. Van Oosterhout A.G., Ganzevles P.G., Wilmink J.T., De Geus B.W., Van Vonderen R.G., Twijnstra A. Sequelae in long-term survivors of small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 1996, 34(5):1037-1044.
94. Von Ah D., Carpenter J.S., Saykin A., Monahan P., Wu J., Yu M., et al. Advanced cognitive training for breast cancer survivors: A randomized controlled trial. Breast Cancer Research and Treatment 2012, 135(3):799-809.
95. Walker L.G., Walker M.B., Heys S.D., Lolley J., Wesnes K.E. The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. Psychooncology 1997, 6(4):290-301.
96. Walker L.G., Wesnes K.P., Heys S.D., Walker M.B., Lolley J., Eremin O. The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: A controlled clinical trial using computerised assessments. European Journal Cancer 1996, 32A(13):2275-2283.
97. Weaver K.E., Foraker R.E., Alfano C.M., Rowland J.H., Arora N.K., Bellizzi K.M., et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: A gap in survivorship care?. Journal Cancer Survivorship 2013, 7(2):253-261.
98. Weaver K.E., Geiger A.M., Lu L., Case L.D. Rural-urban disparities in health status among US cancer survivors. Cancer 2013, 119(5):1050-1057.
99. Weaver K.E., Palmer N., Lu L., Case L.D., Geiger A.M. Rural-urban differences in health behaviors and implications for health status among US cancer survivors. Cancer Causes Control 2013, 24(8):1481-1490.
100. Wefel J.S., Lenzi R., Theriault R., Buzdar A.U., Cruickshank S., Meyers C.A. 'Chemobrain' in breast carcinoma?: A prologue. Cancer 2004, 101(3):466-475.
101. Wefel J.S., Lenzi R., Theriault R.L., Davis R.N., Meyers C.A. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer 2004, 100(11):2292-2299.
102. Wefel J.S., Saleeba A.K., Buzdar A.U., Meyers C.A. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 2010, 116(14):3348-3356.
103. Yancik R., Wesley M.N., Ries L.A., Havlik R.J., Edwards B.K., Yates R. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001, 285(7):885-892.